Reis, João Pedro Nassar; Umeta, Pedro Fukui; Stefano, José Tadeu 
; Longatto Filho, Adhemar ; Carrilho, Flair José ; Alves, Venancio Avancini Ferreira ; Cogliati, Bruno ; Oliveira, Cláudia Pinto Marques Souza de
Source: Journal of Molecular Histology. Unidades: FM, FMVZ
Subjects: CARCINOMA HEPATOCELULAR, HEPATITE, INIBIDORES DE ENZIMAS, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REIS, João Pedro Nassar et al. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC. Journal of Molecular Histology, v. 54, p. 473-488, 2023Tradução . . Disponível em: https://doi.org/10.1007/s10735-023-10142-9. Acesso em: 20 set. 2024.APA
Reis, J. P. N., Umeta, P. F., Stefano, J. T., Longatto Filho, A., Carrilho, F. J., Alves, V. A. F., et al. (2023). P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC. Journal of Molecular Histology, 54, 473-488. doi:10.1007/s10735-023-10142-9NLM
Reis JPN, Umeta PF, Stefano JT, Longatto Filho A, Carrilho FJ, Alves VAF, Cogliati B, Oliveira CPMS de. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC [Internet]. Journal of Molecular Histology. 2023 ; 54 473-488.[citado 2024 set. 20 ] Available from: https://doi.org/10.1007/s10735-023-10142-9Vancouver
Reis JPN, Umeta PF, Stefano JT, Longatto Filho A, Carrilho FJ, Alves VAF, Cogliati B, Oliveira CPMS de. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC [Internet]. Journal of Molecular Histology. 2023 ; 54 473-488.[citado 2024 set. 20 ] Available from: https://doi.org/10.1007/s10735-023-10142-9
